Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.59 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516076 | 0.89 | HDAC1 (0.62) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL24359615 | 0.88 | HDAC1 (0.67) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29516151 | 0.84 | HDAC1 (0.61) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29516132 | 0.84 | HDAC1 (0.64) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29516173 | 0.84 | HDAC1 (0.66) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29516155 | 0.82 | HDAC1 (0.64) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29515970 | 0.82 | HDAC1 (0.59) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL24359487 | 0.82 | HDAC1 (0.69) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29516174 | 0.81 | HDAC1 (0.57) | HDAC1HDAC2HDAC6HDAC3HDAC10 | |
| SCHEMBL29516335 | 0.80 | MEN1 (0.61) | HDAC1HDAC2HDAC6HDAC3HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327427-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2022087456-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327427-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN2, PSEN1, CHAT | HDAC1 1254/4885HDAC2 1592/4885HDAC6 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.